Connection
Steven Coultrap to Mutation
This is a "connection" page, showing publications Steven Coultrap has written about Mutation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.253 |
|
|
|
-
Larsen ME, Barker CM, Vargas RS, Coultrap SJ, Bayer KU. The CaMKII D135N mutation blocks kinase activity and reduces GluN2B binding. Mol Pharmacol. 2026 May-Jun; 108(5-6):100127.
Score: 0.107
-
Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6.
Score: 0.048
-
Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
Score: 0.039
-
Brown CN, Barker CM, Miller CN, Chao FY, Aoto J, Coultrap SJ, Bayer KU. CaMKII monomers are sufficient for GluN2B binding, co-condensation, and synaptic potentiation. Mol Cell. 2026 10 01; 86(19):4004-4017.e6.
Score: 0.027
-
Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
Score: 0.017
-
Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|